Literature DB >> 24029796

Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.

Ariel Berger1, John Edelsberg, Gerry Oster, Xingyue Huang, David J Weber.   

Abstract

BACKGROUND: Although clinical guidelines for management of community-acquired pneumonia (CAP) in non-intensive care unit ("non-ICU") hospitalized patients have changed substantially over the last decade, it is unknown how treatment of this disease has evolved over this period.
METHODS: Using data from >100 U.S. hospitals, we identified all adults (aged ≥18 years) hospitalized for CAP between January 1, 2000, and June 30, 2009 ("study period"). We excluded patients admitted to ICU <24 hours of admission, those not starting antibiotics <24 hours of admission, those not receiving antibiotics for ≥48 hours (if alive), and those with probable healthcare-associated pneumonia. We defined "initial therapy" as all parenteral antibiotics received ≤24 hours of admission, and we examined changes in such therapy over the study period. The statistical significance of changes in initial therapy was ascertained using 2-tailed χ tests.
RESULTS: We identified 40,392 patients who met all selection criteria. In 2000, the most frequently used initial regimens were levofloxacin (24.0% of all such admissions), ceftriaxone (9.0%), cefotaxime (7.3%), ceftriaxone plus levofloxacin (3.2%) and azithromycin plus cefotaxime (3.0%); in 2009, they were ceftriaxone plus azithromycin (18.5%), levofloxacin (12.7%), ceftriaxone (6.6%), moxifloxacin (4.7%) and ceftriaxone + levofloxacin (3.2%). Use of single-agent regimens declined between 2000 and 2009 (from 48.2%-30.0%); use of vancomycin almost doubled (13.1%-23.3%). All findings were statistically significant (P < 0.01).
CONCLUSIONS: Initial antibiotic therapy for non-ICU CAP has changed substantially in the United States over the past decade, in line with evidence of widespread antibiotic resistance, evolving treatment guidelines and, most recently, quality improvement initiatives that tie hospital payments to guideline-based care.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24029796     DOI: 10.1097/MAJ.0b013e318294833f

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  12 in total

1.  Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study.

Authors:  Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks
Journal:  Open Forum Infect Dis       Date:  2017-06-20       Impact factor: 3.835

2.  Journal Club: Long-term functional outcome in patients with acquired infections after acute spinal cord injury.

Authors:  Freda M Warner; Bobo Tong; Catherine R Jutzeler; Jacquelyn J Cragg; Paulina S Scheuren; John L K Kramer
Journal:  Neurology       Date:  2017-08-15       Impact factor: 9.910

3.  Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL: A Pilot Randomized Controlled Trial.

Authors:  Joseph R Paonessa; Raj D Shah; Chiagozie I Pickens; Bryan D Lizza; Helen K Donnelly; Michael Malczynski; Chao Qi; Richard G Wunderink
Journal:  Chest       Date:  2019-02-15       Impact factor: 9.410

4.  Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.

Authors:  Brandon J Webb; Kristin Dascomb; Edward Stenehjem; Holenarasipur R Vikram; Neera Agrwal; Kenneth Sakata; Kathryn Williams; Bruno Bockorny; Kavitha Bagavathy; Shireen Mirza; Mark Metersky; Nathan C Dean
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.

Authors:  Barbara Ellen Jones; Jian Ying; Vanessa Stevens; Candace Haroldsen; Tao He; McKenna Nevers; Matthew A Christensen; Richard E Nelson; Gregory J Stoddard; Brian C Sauer; Peter M Yarbrough; Makoto M Jones; Matthew Bidwell Goetz; Tom Greene; Matthew H Samore
Journal:  JAMA Intern Med       Date:  2020-04-01       Impact factor: 21.873

6.  Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.

Authors:  Barbara E Jones; Makoto M Jones; Benedikt Huttner; Gregory Stoddard; Kevin Antoine Brown; Vanessa W Stevens; Tom Greene; Brian Sauer; Karl Madaras-Kelly; Michael Rubin; Matthew Bidwell Goetz; Matthew Samore
Journal:  Clin Infect Dis       Date:  2015-07-29       Impact factor: 9.079

7.  Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency.

Authors:  Meng Zhong; Yue Feng; Hong Liao; Xueyuan Hu; Shengli Wan; Biyue Zhu; Mi Zhang; Huarong Xiong; Yunli Zhou; Jingqing Zhang
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

8.  Adaptation of antibiotic treatment to clinical practice guidelines in patients aged ⩾65 years hospitalised due to community-acquired pneumonia.

Authors:  M A Fernandez-Sierra; M T Rueda-Domingo; M M Rodriguez-Del-Aguila; M J Perez-Lozano; L Force; T Fernandez-Villa; J Astray; M Egurrola; J Castilla; F Sanz; D Toledo; A Dominguez
Journal:  Epidemiol Infect       Date:  2018-08-02       Impact factor: 4.434

Review 9.  The global threat of antimicrobial resistance: science for intervention.

Authors:  I Roca; M Akova; F Baquero; J Carlet; M Cavaleri; S Coenen; J Cohen; D Findlay; I Gyssens; O E Heuer; G Kahlmeter; H Kruse; R Laxminarayan; E Liébana; L López-Cerero; A MacGowan; M Martins; J Rodríguez-Baño; J-M Rolain; C Segovia; B Sigauque; E Tacconelli; E Wellington; J Vila
Journal:  New Microbes New Infect       Date:  2015-04-16

Review 10.  Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of recommendations.

Authors:  Marco Mantero; Paolo Tarsia; Andrea Gramegna; Sonia Henchi; Nicolò Vanoni; Marta Di Pasquale
Journal:  Multidiscip Respir Med       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.